Circassia Share Discussion Threads

[neilyb675] 10/1/2020 21:53

Wow, this is an exciting investment. Loving it.

[100egs] 10/1/2020 18:17

Late reported TR1 from oryx, should be interesting next week with such huge demand from institutions

[74tom] 10/1/2020 17:46

Confirmation that CIP were the 12m buyer this morning then. Also 3m of late reported buys, the 2.5m at 10.14 being the buy that shot us through the 23p barrier. A tremendous day/week - surely the start of a long upward re-rate to fair value. You would imagine other funds will snap up the remaining 32m Invesco shares in the next couple of weeks off the back of yesterday’s RNS...

[pro_s2009] 10/1/2020 16:56

A strong management team whose leader has options if they get the share price over 62p.... :)


The Options have been granted at nil-cost and will vest on the third anniversary of the date of grant and are exercisable until the tenth anniversary of the date of grant. Vesting is subject to either the share price reaching 62.4p, equating to three times the average closing price for an Ordinary Share for the 10 dealing days immediately preceding the grant date, for at least 30 consecutive dealing days or a liquidity event occurring above this level.

[100egs] 10/1/2020 16:38

Note one of the main reasons for CIP investing is the strong Management team now in place..echoes my sentiments. whats not to like about CIR

[sphere25] 10/1/2020 16:20

Taken a starter position earlier today at 22p as a short term trade.

Speculative one but there is clearly very serious demand for stock here with the overhang specialists at Invesco being cleared out rapidly. That chart is starting to give the horn too.

If this breaks 24 next week and then closes above 25p, I'll be adding at each point as the stock is probably going to go screaming north so I'll be watching closely. If it fails, it's just going to fart around in a small range near current levels so not a huge risk.

Easily one of the more interesting trades on the radar.

Roll on next week!

[linton5] 10/1/2020 16:14

I know it sounds stupid to some but I’m adding at 25p as on the weekly chart resistance is 24.8 next resistance is 48p after That,patience definitely a 1 to 2 year hold

[donald pond] 10/1/2020 16:03

Well, chart is looking tasty, fundamentals look great, smart money getting in, moving from burning money to making it: what's not to like?

[pro_s2009] 10/1/2020 16:00

Yes, good news indeed.

[andyview] 10/1/2020 15:32

Probably helps to explain the support and increase in the price - very encouraging from my perspective.


gla

[bc4] 10/1/2020 15:26

("CIP Merchant Capital", "CIP" or the "Company")

Investment in Circassia Pharmaceuticals plc

CIP Merchant Capital is pleased to announce its investment in Circassia Pharmaceuticals plc ("Circassia"), a specialty biopharmaceutical company focused on allergy and respiratory diseases quoted on AIM. The Company has acquired, in aggregate, 12,800,000 ordinary shares in Circassia, representing approximately 3.4% of Circassia issued share capital, for a total consideration of approximately GBP2.8 million.

In the year ended 31 December 2018, Circassia had revenue of GBP48.3 million, a gross profit of GBP39.4 million and a net loss attributable to its shareholders of GBP25.9 million from underlying operations and a total loss of GBP117.1 million, which includes losses of GBP20.7 million from non-underlying operations (non-recurring/irregular expenditure) and loss of GBP70.5 million from discontinued operations. In the six months ended 30 June 2019, Circassia reported revenue of GBP27.9 million, a gross profit of GBP20.3 million and a total loss of GBP19.0 million, and, as at 30 June 2019, had net assets of GBP103.2 million.

The Board of CIP believes Circassia has a clear route to profitability, having recently announced that the revenues for the 2019 year are expected to fall in the mid-range of its previously issued guidance of GBP60-GBP65 million. In April 2019, Circassia announced the US Food and Drug Administration approval of Duaklir, a drug for maintenance treatment of chronic obstructive pulmonary disease, which was later launched in October 2019. Circassia has also recently made what the Board believes to be positive changes to its leadership team, hiring executives with a proven track record.

[andyview] 10/1/2020 15:24

Reassuring investment - the latest RNS - i've added a few more - showing as a sell obvs!

gla

[pro_s2009] 10/1/2020 13:07

RG announced he has reduced his JOG holding - more CIR buying for him soon ?

[74tom] 10/1/2020 11:51

Great to see at least 12m invesco shares snapped up this morning - looked most likely to be an exchange at 21.5p rather than 2 x 12m buys but we won’t know for sure until we get the next holdings RNS. The rise is still being controlled by AT trades and will continue to be until Invesco are out fully, I’d expect us to be at 30p + by the time this happens though. This really is an opportunity of a lifetime IMO. Double/triple you money in a relatively short time frame!

[pro_s2009] 10/1/2020 10:38

NIOX sales in China were up nearly 200% at the interims, massive growth there.

And the new version will also enhance more sales growth moving forward.



.

[pro_s2009] 10/1/2020 10:24

Massive growth......sad for them, although there is a silver lining in every cloud, and that silver lining is for CIR sales growth.



.

[pro_s2009] 10/1/2020 09:56

Yes, in due course those target prices are going to rise and rise, as this turns EBITDA profitable and then into making real profits so those target prices will rise.

I mean...........its in the right sector (respiratory illness is increasing), its healthcare.........its the perfect investment.

[m5] 10/1/2020 09:32

Moving now. I see chart wise maybe a little resistance at 25p, minor, then up to 30p, and from then on its up to 45p which is still a long way from the brokers target of 80p. Lots of blue sky ahead. Please DYOR.


free stock charts from uk.advfn.com

[timmy11] 10/1/2020 08:45

actually 2x 12million

[neilyb675] 10/1/2020 08:44

21.80 - 22.00 (GBX) at 08:41:24
on Market (LSE)